Description
Methenolone Acetate (Primobolan Oral, Primo Tabs) is the oral acetate ester variant of Methenolone, a 5α-reduced DHT derivative. The oral form differs from the injectable variant (Methenolone Enanthate) primarily in bioavailability - the acetate ester survives first-pass hepatic metabolism substantially better than the unesterified form.
Per study reports Methenolone binds weakly to moderately to the androgen receptor and doesn’t aromatize. Anabolic action is mild - comparable to Anavar in strength. The missing aromatization and low androgenic profile make Primo Oral the preferred compound in women’s research setups and in cutting phases where water retention should be avoided.
The central limitation is bioavailability: despite acetate ester modification oral availability is only about 22%. This requires high daily doses (50-100mg+) to achieve effective plasma levels. Compared to the injectable form Primo Oral is often economically unfavorable.
Pharmacokinetically orally bioavailable with about 4-6 hour half-life. Research protocols therefore require 2-3 daily doses.
Known effects in studies: very mild side effect profile compared to classical 17α-methyl steroids. Low hepatotoxicity, low HPG suppression, no estrogen effect. The main disadvantage remains bioavailability and thus cost.
Methenolone is on the WADA banned list.
You can order Primobolan Oral as tablets in one bottle with 25mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Methenolone Acetate is considered a very mild oral anabolic per study reports, yet still sits in the upper range of the risk scale. The effects documented in the literature are milder than under classical 17α-methyl steroids.
Documented in studies and the user literature:
- Low liver strain: in the literature, Methenolone is described as low in hepatotoxicity, substantially milder than classical alkylated orals.
- Lipid profile: an unfavorable shift of the lipid profile is documented in studies, as is typical for oral anabolics.
- Suppression of natural production: a low but present HPG suppression is described in the literature.
- Low bioavailability: an oral availability of only about 22 percent is documented, requiring high daily doses.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Anabolic Androgenic Steroids in the Treatment of Acquired Aplastic Anemia - Blood 1969: classic clinical hematology study on the use of anabolic androgens including methenolone in acquired aplastic anemia.
- Treatment of Refractory Anemias with Methenolone - Acta Medica Scandinavica 1979: therapeutic trial in 19 patients with various refractory anemias under methenolone (Primobolan), including remission rates per subtype.
- Partial remission and severe adverse effect caused by metenolone acetate in a male patient with aplastic anemia - European Journal of Haematology 1995: case report of a male patient on metenolone acetate with partial hematologic remission and severe adverse effects.
- Fatal outcome of a patient with severe aplastic anemia after treatment with metenolone acetate - Annals of Hematology 1993: case report with marked transaminase elevation and fatal hepatic failure under metenolone acetate treatment.
- Effect of methenolone enanthate (NSC-64967) in advanced cancer of the breast - Cancer 1968, Kennedy et al: early randomized clinical oncology trial on the parent compound methenolone (enanthate ester) in advanced breast cancer with objective response in 48 percent of patients.
